copanlisib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
phosphatidylinositol 3-kinase inhibitors, antineoplastics 5256 1032568-63-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • copanlisib
  • BAY 80-6946
  • BAY 84-1236
  • copanlisib hydrochloride
  • copanlisib HCl
  • copanlisib hydrochloride hydrate
Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells. Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Copanlisib inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFkB signaling in lymphoma cell lines.
  • Molecular weight: 480.53
  • Formula: C23H28N8O4
  • CLOGP: 0.91
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 2
  • TPSA: 139.79
  • ALOGS: -3.32
  • ROTB: 7
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6.43 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 10.34 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.42 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 25.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 14, 2017 FDA BAYER HEALTHCARE PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to muscle 64.12 47.41 9 586 351 79743442
Cytopenia 63.57 47.41 17 578 20366 79723427
Metastases to retroperitoneum 63.09 47.41 9 586 395 79743398
Metastases to spleen 58.89 47.41 9 586 635 79743158
Neutropenic sepsis 58.80 47.41 17 578 27047 79716746
Metastases to bone marrow 56.70 47.41 9 586 813 79742980
End stage renal disease 51.71 47.41 13 582 12207 79731586
Pyrexia 50.93 47.41 41 554 678668 79065125

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EM02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Phosphatidylinositol-3-kinase (Pi3K) inhibitors
FDA MoA N0000175082 Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50914 PI(3)K inhibitor
CHEBI has role CHEBI:68495 Type I cell-death inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Follicular lymphoma indication 55150002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.78 acidic
pKa2 9.17 Basic
pKa3 7.65 Basic
pKa4 6.36 Basic
pKa5 2.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase INHIBITOR IC50 9.16 SCIENTIFIC LITERATURE DRUG LABEL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase INHIBITOR IC50 9.30 SCIENTIFIC LITERATURE DRUG LABEL
Serine/threonine-protein kinase mTOR Kinase INHIBITOR IC50 7.35 IUPHAR
Ras-related protein Rab-27A Enzyme Kd 5.35 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Kinase INHIBITOR IC50 8.43 SCIENTIFIC LITERATURE
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Kinase INHIBITOR IC50 8.19 SCIENTIFIC LITERATURE

External reference:

IDSource
WI6V529FZ9 UNII
1402152-13-9 SECONDARY_CAS_RN
1402152-46-8 SECONDARY_CAS_RN
4036879 VANDF
C4049141 UMLSCUI
CHEBI:173077 CHEBI
6E2 PDB_CHEM_ID
CHEMBL3218576 ChEMBL_ID
135565596 PUBCHEM_CID
DB12483 DRUGBANK_ID
CHEMBL3545068 ChEMBL_ID
D10797 KEGG_DRUG
9726 INN_ID
7875 IUPHAR_LIGAND_ID
d08659 MMSL
017343 NDDF
741057007 SNOMEDCT_US
763592006 SNOMEDCT_US
1945077 RXNORM
C000589253 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ALIQOPA HUMAN PRESCRIPTION DRUG LABEL 1 50419-385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 29 sections
ALIQOPA HUMAN PRESCRIPTION DRUG LABEL 1 50419-385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 29 sections
ALIQOPA HUMAN PRESCRIPTION DRUG LABEL 1 50419-385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 29 sections